News

We’ve compiled a list of noteworthy recall statements from this past week.

A summary of Contagion's top stories for May 15, 2020.

Elizabeth Leung, PharmD, shares SIDP's educational efforts surrounding COVID-19 treatment.

An antibody candidate from Sorrento has shown complete blockage of infection in early assessments. The company is now pursuing production and regulatory aid.

New research into a combination of antiviral therapies finds it is safe and appears to shorten disease course in patients with early coronavirus.

A new first-of-its-kind global registry aimed at sharing real-time information on hospital care and ICU admissions could expand the scope of SARS-CoV-2 research.

A briefing on the day's top stories.

In an in vitro reconstituted human respiratory epithelium model, the investigational drug inhibited replication of the novel coronavirus.

The first-of-its-kind, randomized, placebo-controlled, phase 1/2a trial will assess patients hospitalized at Florida and South Dakota institutions.

New findings comparing cases since February to the last half-decade show the rate and severity of the rare inflammatory disease recently spiked in children.

Vaccine candidate mRNA-1273 has been granted Fast Track designation by the US FDA.

A summary of today's top stories.

Barriers to recommended vaccine coverage for low-income American adults include disparity in Medicaid programs and low reimbursement amounts, a new study found.

Efforts to speed diagnosis among men might help stem the spread of the disease.

Paul Sax, MD, discusses remdesivir, scientific literature in the age of COVID-19, and the pandemic's long-lasting effects on the future of health care.

A series of essays consider the privileges and ethics of an immunity-based "passport" to proceed with fewer restrictions in the age of COVID-19.

Treating severe COVID-19 patients with lopinavir-ritonavir did not have any significant effect compared to standard-care control patients.

A quick summary of the day's infectious disease headlines.

The agency provided 2 new recommendation guidelines for sponsors looking to assess potential preventive and therapeutic agents for the coronavirus.

What is the hopeful expectation of the new candidates, relative to previously developed vaccines?

RSV causes thousands of deaths in children - why do some have more severe disease?

Rodney E. Rohde, PhD, discusses the challenges our shortage of medical laboratory specialists creates for the COVID-19 response.

Contact tracing allows epidemiological response by not only notifying people of exposure so they can quarantine, but also understanding potential exposure dynamics that allowed for disease transmission.

Conversations about PrEP with a clinician are the least common among adolescents with the greatest risk for HIV.

A brief summary of our daily coverage.

The Rutgers laboratory is now authorized to receive and test collected, prescribed samples of either nasal or saliva samples for possible COVID-19.

Preventive medicine expert William Schaffner, MD, discusses what it will take for investigators to properly assess and manufacture a vaccine.

In a new phase 4 study, investigators found giving patients raxibacumab at the start of anthrax vaccine adsorbed administration does hurt the protective quality of the vaccine.